-
对于恶性肿瘤浅表转移病灶,采用局部外照射放疗或全身化疗都不能取得良好的疗效,患者不良反应较大[1]。手术切除往往不能彻底。随着近距离放射治疗技术的发展,组织间放射粒子植入治疗日益受到重视[2]。本研究对24例胸部肿瘤术后转移性肿瘤患者应用125I粒子行组织间永久性植入治疗,取得了较好的疗效,现报告如下。
-
24例患者无手术死亡,无明显白细胞下降。1周复查血常规恢复正常,肝功能和免疫指标较术前无明显变化。24例肿瘤患者均生存下来,其中3例术后生存6~8个月,手术后局部压迫或疼痛均获不同程度改善。28处瘤灶共植入125I粒子672颗,平均每处24颗,平均每处放射能量为657.6~756.0 keV。植入后1个月经局部B超或CT检查,未见粒子移位。
手术后转移肿瘤局部压迫或疼痛均获不同程度改善。24例患者28处胸部浅表转移肿瘤植入125I粒子1个月后的治疗效果见表 1。胸部浅表转移性肿瘤病灶疼痛症状完全缓解23处,部分缓解5处。125I粒子植入治疗1个月后行B超及CT复查肿瘤体积变化,结果:28处胸部转移瘤病灶中,有25处部分缓解,3处无改变。
0级 1级 2级 3级 植人前 0 0 22 6 植人后 23 2 3 0 表 1 125I粒子植入前后胸部浅表转移瘤灶疼痛程度的变化
(病灶数)
125I粒子永久性组织间植入治疗浅表恶性转移肿瘤
Interstitial permanent implantation of 125I seeds as salvage therapy for superficial metastatic tumor
-
摘要:
目的 探讨125I粒子术中组织间植入治疗浅表恶性转移肿瘤的临床效果。 方法 在B超引导下将125I粒子植入24例恶性肿瘤切除后28处浅表转移病灶肿瘤组织内,治疗1个月后观察疼痛缓解情况和瘤灶大小等变化,并定期随访。 结果 24例患者术后均恢复良好,未因植入125I粒子而导致严重并发症,随访1~14个月,中位随访8个月,均无不良反应发生。125I粒子植入1个月后,肿瘤病灶疼痛症状完全缓解23处,部分缓解5处;肿瘤病灶体积部分缓解25处,3处无改变。 结论 125I粒子组织间植入治疗浅表恶性转移肿瘤,方法简便,近期疗效确切,能缓解癌性疼痛及局部压迫等症状,提高患者的生存质量。 Abstract:Objective To investigate the clinical effect of 125I seeds interstitial permanent implant for superficial metastatic tumor. Methods Under the guidance of the B-ultrasonography, 125I seeds were implanted into 28 units of the superficial metastatic tumor in 24 patients who had been given tumor resection, and the pain relief and tumor size were observed by means of B-ultrasonography and CT regularly after 1 month. Results All the patients were followed-up for 1-14 months, and the median length of follow-up was 8 months. The symptoms recovered well with no adverse reaction after operation. One month after the implantation, the pain symptom was alleviated entirely in 23 lesions and partly in 5 lesions. The tumor size shrank in 25 lesions and there was no change in 3 lesions. Conclusion Radioactive 125I seeds interstitial permanent implantation is a simple, safe, effective method which can improve living quality of patients and ease the pain and local compression. -
Key words:
- Metastatic tumor /
- Iodine radioisotopes /
- Brachytherapy
-
表 1 125I粒子植入前后胸部浅表转移瘤灶疼痛程度的变化
(病灶数) 0级 1级 2级 3级 植人前 0 0 22 6 植人后 23 2 3 0 -
[1] Ragde H, Elgamal AA, Snow PB, et al. Ten-year disease free survival after thransperineal sonography-guided iodine-125 brachytherapy with or without 45-gray external beam irraddiation in the treatment of patients with clinicalized, low to high gleason grade prostate carcinoma. Cancer, 1998, 83(5): 989-1001. [2] Videtic GM, Gaspar LE, Zamorano L, et al. Use of the RTOG recursive partitioning analysis to validate the benefit of iodine-125 implants in the primary treatment of malignant gliomas. Int J Radiat Oncol Biol Phys, 1999, 45(3): 687-692. [3] 孙燕.癌症疼痛处理的基本原则.中国肿瘤, 1999, 8(2): 55-56.
[4] 赵恩民, 肖水芳, 秦永, 等. 125I放射性密封源永久性置入治疗5例晚期头颈部癌疗效观察.临床耳鼻咽喉科杂志, 2004, 18(6): 348-352.
[5] 法逸华, 苏成海, 黄钢. 125I粒子近距离照射在肿瘤治疗中的应用.国外医学放射医学核医学分册, 2003, 27(3): 115.
[6] 王洪武.现代肿瘤靶向治疗技术.北京:中国医药科技出版社, 2004: 324-353.
[7] 申文江, 王绿化, 夏延毅.放射治疗学新技术进展.北京:北京科学技术出版社, 2003: 199-200.